Artelo Biosciences, Inc. (ARTL) 10-Year Financial Performance & Capital Metrics

ARTL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutArtelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Show more

Revenue $0
EBITDA -$10M -1.8%
Net Income -$10M -5.8%
EPS (Diluted) -3.05 +2.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -134.52% -125.6%
ROIC -158.22% -128.8%
Debt/Equity 0.04 +1760.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.62%

EPS CAGR

10Y-

5Y-

3Y-

TTM-68.08%

ROCE

10Y Avg-590.49%

5Y Avg-92.03%

3Y Avg-88.89%

Latest-137.73%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	15.24K	29.69K	232.79K	2.34M	3.21M	4.69M	7.44M	10.29M	9.93M	10.11M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	15.24K	29.69K	232.79K	1.09M	2.12M	2.77M	4.6M	5.96M	4.23M	4.12M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	0	1.25M	1.09M	1.92M	2.84M	4.32M	5.7M	5.99M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	1.41K	0	0	0	0
Operating Income+	-15.24K	-29.69K	-232.79K	-2.34M	-3.21M	-4.69M	-7.44M	-10.29M	-9.93M	-10.11M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0%	-0.95%	-6.84%	-9.07%	-0.37%	-0.46%	-0.59%	-0.38%	0.03%	-0.02%
EBITDA+	-15.24K	-6.87K	-232.19K	-2.34M	-3.21M	-4.69M	-7.44M	-10.08M	-9.93M	-10.11M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0%	0.55%	-32.78%	-9.09%	-0.37%	-0.46%	-0.59%	-0.36%	0.01%	-0.02%
D&A (Non-Cash Add-back)	0	22.82K	600	282	510	500	0	0	0	0
EBIT	0	0	-232.79K	-2.34M	0	0	-7.44M	-10.08M	-9.93M	-10.11M
Net Interest Income+	0	0	-2.1K	0	0	0	2K	-3K	0	0
Interest Income	0	0	0	0	0	0	2K	2K	0	0
Interest Expense	0	0	2.1K	0	0	0	0	5K	0	0
Other Income/Expense	0	0	-2.1K	0	1.04M	30K	4K	204K	641K	282K
Pretax Income+	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.66M	-7.44M	-10.08M	-9.29M	-9.83M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	8	-2.04M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.65M	-7.44M	-10.08M	-9.29M	-9.83M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0%	-0.95%	-6.91%	-8.98%	0.07%	-1.14%	-0.6%	-0.36%	0.08%	-0.06%
Net Income (Continuing)	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.65M	-7.44M	-10.08M	-9.29M	-9.83M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.24	-0.47	-3.23	-27.52	-15.00	-18.83	-5.97	-3.49	-3.14	-3.05
EPS Growth %	0.6%	-0.96%	-5.87%	-7.52%	0.45%	-0.26%	0.68%	0.42%	0.1%	0.03%
EPS (Basic)	-0.24	-0.47	-3.23	-27.52	-15.00	-18.83	-5.97	-3.49	-3.14	-3.05
Diluted Shares Outstanding	10.61K	10.61K	12.13K	14.2K	24.14K	41.2K	207.5K	472.17K	2.96M	3.22M
Basic Shares Outstanding	10.61K	10.5K	12K	14K	24K	41.17K	207.5K	472K	2.96M	3.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.03K	3.59K	574.27K	396.44K	4.44M	2.34M	10.32M	18.32M	10.98M	2.56M
Cash & Short-Term Investments	17.03K	3.59K	572.77K	337.42K	4.42M	2.14M	10.06M	17.53M	10.43M	2.34M
Cash Only	17.03K	3.59K	572.77K	337.42K	4.42M	2.14M	6.63M	6.89M	2.81M	2.34M
Short-Term Investments	0	0	0	0	0	0	3.44M	10.64M	7.61M	0
Accounts Receivable	0	0	0	22.13K	8.79K	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	-8.79K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	1.5K	36.88K	18.62K	195.13K	252K	789K	554K	219K
Total Non-Current Assets+	0	0	0	563	2.04M	2.04M	2.32M	2.1M	2.06M	2.14M
Property, Plant & Equipment	0	0	0	563	721	246	90K	60K	21K	99K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	2.04M	2.04M	2.04M	2.04M	2.04M	2.04M
Long-Term Investments	0	0	0	0	0	0	0	-1.5M	0	0
Other Non-Current Assets	0	0	0	0	0	0	189K	3K	3K	3K
Total Assets+	17.03K	3.59K	574.27K	397K	6.48M	4.38M	12.63M	20.42M	13.04M	4.7M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.16%	-0.79%	158.97%	-0.31%	15.33%	-0.32%	1.89%	0.62%	-0.36%	-0.64%
Total Current Liabilities+	1.74K	17.39K	29.44K	531.97K	1.02M	502.18K	526K	998K	1.29M	1.77M
Accounts Payable	0	12.94K	28.58K	529.27K	348.86K	490.22K	493K	905K	1.24M	1.68M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	28K	40K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.74K	4.45K	862	2.7K	672.65K	-478.26K	-488K	-852K	0	-3K
Current Ratio	9.79x	0.21x	19.51x	0.75x	4.35x	4.65x	19.61x	18.36x	8.51x	1.44x
Quick Ratio	9.79x	0.21x	19.51x	0.75x	4.36x	4.65x	19.61x	18.36x	8.51x	1.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	12.94K	28.58K	529.27K	348.86K	490.22K	67K	23K	0	69K
Long-Term Debt	0	0	0	0	0	0	67K	23K	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	69K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	348.86K	490.22K	0	0	0	0
Total Liabilities	1.74K	17.39K	29.44K	531.97K	1.02M	502.18K	593K	1.02M	1.29M	1.84M
Total Debt+	0	0	0	0	0	0	95K	63K	23K	104K
Net Debt	-17.03K	-3.59K	-572.77K	-337.42K	-4.42M	-2.14M	-6.53M	-6.83M	-2.79M	-2.23M
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-110.85x	-	-	-	-	-2057.40x	-	-
Total Equity+	15.29K	-13.8K	544.84K	-134.97K	5.46M	3.87M	12.04M	19.4M	11.75M	2.86M
Equity Growth %	0.04%	-1.9%	40.48%	-1.25%	41.46%	-0.29%	2.11%	0.61%	-0.39%	-0.76%
Book Value per Share	1.44	-1.30	44.92	-9.51	226.25	94.06	58.03	41.09	3.97	0.89
Total Shareholders' Equity	15.29K	-13.8K	544.84K	-134.97K	5.46M	3.87M	12.04M	19.4M	11.75M	2.86M
Common Stock	7.64K	7.64K	11.33K	14K	3.35K	4.99K	25K	3K	3K	3K
Retained Earnings	-30.51K	-60.2K	-295.09K	-2.64M	-4.81M	-9.47M	-16.9M	-31.02M	-40.31M	-50.14M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	0	0	657	-12.28K	-9.81K	63.76K	18K	-254K	-203K	-202K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.5K	-18.49K	-216.82K	-1.61M	-2.79M	-4.35M	-6.14M	-8.01M	-8.21M	-8.35M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.12%	-0.37%	-10.73%	-6.43%	-0.73%	-0.56%	-0.41%	-0.3%	-0.02%	-0.02%
Net Income	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.65M	-7.44M	-10.08M	-9.29M	-9.83M
Depreciation & Amortization	0	0	600	282	510	500	0	0	0	0
Stock-Based Compensation	0	0	3.33K	290K	425.11K	377.77K	1.53M	2.46M	1.02M	818K
Deferred Taxes	0	0	-600	0	-1.01M	0	0	0	0	0
Other Non-Cash Items	0	0	600	0	100K	-29.5K	7K	-211K	-641K	-279K
Working Capital Changes	1.74K	11.2K	14.14K	443.19K	-140.02K	-41.28K	-242K	-172K	703K	937K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	1.74K	11.2K	15.64K	500.7K	-180.41K	127.98K	-3K	23K	273K	480K
Cash from Investing+	0	0	0	-845	-1.5M	0	-3.44M	2.96M	3.51M	7.77M
Capital Expenditures	0	0	0	-845	-1.5M	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	15.8K	5.05K	785.35K	1.39M	8.38M	1.98M	14.11M	0	567K	112K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	5.05K	42.67K	1.84K	1.05K	3.15K	6.01M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.5K	-18.49K	-216.82K	-1.61M	-4.29M	-4.35M	-6.14M	-8.01M	-8.21M	-8.35M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.12%	-0.37%	-10.73%	-6.43%	-1.67%	-0.01%	-0.41%	-0.3%	-0.02%	-0.02%
FCF per Share	-1.27	-1.74	-17.88	-113.48	-177.86	-105.53	-29.60	-16.96	-2.77	-2.59
FCF Conversion (FCF/Net Income)	0.89x	0.62x	0.92x	0.69x	1.29x	0.93x	0.83x	0.79x	0.88x	0.85x
Interest Paid	-	-	-	-	-	-	-	-	0	0
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-101.54%	-3985.23%	-88.46%	-1143.55%	-81.57%	-99.72%	-93.45%	-64.13%	-59.63%	-134.52%
Return on Invested Capital (ROIC)	-	-	-	-	-852.31%	-253.77%	-154.15%	-85.32%	-69.16%	-158.22%
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x	0.04x
Interest Coverage	-	-	-110.85x	-	-	-	-	-2057.40x	-	-
FCF Conversion	0.89x	0.62x	0.92x	0.69x	1.29x	0.93x	0.83x	0.79x	0.88x	0.85x

Frequently Asked Questions

Growth & Financials

Artelo Biosciences, Inc. (ARTL) grew revenue by 0.0% over the past year. Growth has been modest.

Artelo Biosciences, Inc. (ARTL) reported a net loss of $10.5M for fiscal year 2024.

Dividend & Returns

Artelo Biosciences, Inc. (ARTL) has a return on equity (ROE) of -134.5%. Negative ROE indicates the company is unprofitable.

Artelo Biosciences, Inc. (ARTL) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Artelo Biosciences, Inc. (ARTL) 10-Year Financial Performance & Capital Metrics

ARTL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$10M -1.8%
Net Income -$10M -5.8%
EPS (Diluted) -3.05 +2.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -134.52% -125.6%
ROIC -158.22% -128.8%
Debt/Equity 0.04 +1760.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.62%

EPS CAGR

10Y-

5Y-

3Y-

TTM-68.08%

ROCE

10Y Avg-590.49%

5Y Avg-92.03%

3Y Avg-88.89%

Latest-137.73%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-	-	-
Operating Expenses+	15.24K	29.69K	232.79K	2.34M	3.21M	4.69M	7.44M	10.29M	9.93M	10.11M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	15.24K	29.69K	232.79K	1.09M	2.12M	2.77M	4.6M	5.96M	4.23M	4.12M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	0	1.25M	1.09M	1.92M	2.84M	4.32M	5.7M	5.99M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	1.41K	0	0	0	0
Operating Income+	-15.24K	-29.69K	-232.79K	-2.34M	-3.21M	-4.69M	-7.44M	-10.29M	-9.93M	-10.11M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0%	-0.95%	-6.84%	-9.07%	-0.37%	-0.46%	-0.59%	-0.38%	0.03%	-0.02%
EBITDA+	-15.24K	-6.87K	-232.19K	-2.34M	-3.21M	-4.69M	-7.44M	-10.08M	-9.93M	-10.11M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0%	0.55%	-32.78%	-9.09%	-0.37%	-0.46%	-0.59%	-0.36%	0.01%	-0.02%
D&A (Non-Cash Add-back)	0	22.82K	600	282	510	500	0	0	0	0
EBIT	0	0	-232.79K	-2.34M	0	0	-7.44M	-10.08M	-9.93M	-10.11M
Net Interest Income+	0	0	-2.1K	0	0	0	2K	-3K	0	0
Interest Income	0	0	0	0	0	0	2K	2K	0	0
Interest Expense	0	0	2.1K	0	0	0	0	5K	0	0
Other Income/Expense	0	0	-2.1K	0	1.04M	30K	4K	204K	641K	282K
Pretax Income+	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.66M	-7.44M	-10.08M	-9.29M	-9.83M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	8	-2.04M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.65M	-7.44M	-10.08M	-9.29M	-9.83M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0%	-0.95%	-6.91%	-8.98%	0.07%	-1.14%	-0.6%	-0.36%	0.08%	-0.06%
Net Income (Continuing)	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.65M	-7.44M	-10.08M	-9.29M	-9.83M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.24	-0.47	-3.23	-27.52	-15.00	-18.83	-5.97	-3.49	-3.14	-3.05
EPS Growth %	0.6%	-0.96%	-5.87%	-7.52%	0.45%	-0.26%	0.68%	0.42%	0.1%	0.03%
EPS (Basic)	-0.24	-0.47	-3.23	-27.52	-15.00	-18.83	-5.97	-3.49	-3.14	-3.05
Diluted Shares Outstanding	10.61K	10.61K	12.13K	14.2K	24.14K	41.2K	207.5K	472.17K	2.96M	3.22M
Basic Shares Outstanding	10.61K	10.5K	12K	14K	24K	41.17K	207.5K	472K	2.96M	3.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	17.03K	3.59K	574.27K	396.44K	4.44M	2.34M	10.32M	18.32M	10.98M	2.56M
Cash & Short-Term Investments	17.03K	3.59K	572.77K	337.42K	4.42M	2.14M	10.06M	17.53M	10.43M	2.34M
Cash Only	17.03K	3.59K	572.77K	337.42K	4.42M	2.14M	6.63M	6.89M	2.81M	2.34M
Short-Term Investments	0	0	0	0	0	0	3.44M	10.64M	7.61M	0
Accounts Receivable	0	0	0	22.13K	8.79K	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	-8.79K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	1.5K	36.88K	18.62K	195.13K	252K	789K	554K	219K
Total Non-Current Assets+	0	0	0	563	2.04M	2.04M	2.32M	2.1M	2.06M	2.14M
Property, Plant & Equipment	0	0	0	563	721	246	90K	60K	21K	99K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	2.04M	2.04M	2.04M	2.04M	2.04M	2.04M
Long-Term Investments	0	0	0	0	0	0	0	-1.5M	0	0
Other Non-Current Assets	0	0	0	0	0	0	189K	3K	3K	3K
Total Assets+	17.03K	3.59K	574.27K	397K	6.48M	4.38M	12.63M	20.42M	13.04M	4.7M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.16%	-0.79%	158.97%	-0.31%	15.33%	-0.32%	1.89%	0.62%	-0.36%	-0.64%
Total Current Liabilities+	1.74K	17.39K	29.44K	531.97K	1.02M	502.18K	526K	998K	1.29M	1.77M
Accounts Payable	0	12.94K	28.58K	529.27K	348.86K	490.22K	493K	905K	1.24M	1.68M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	28K	40K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.74K	4.45K	862	2.7K	672.65K	-478.26K	-488K	-852K	0	-3K
Current Ratio	9.79x	0.21x	19.51x	0.75x	4.35x	4.65x	19.61x	18.36x	8.51x	1.44x
Quick Ratio	9.79x	0.21x	19.51x	0.75x	4.36x	4.65x	19.61x	18.36x	8.51x	1.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	12.94K	28.58K	529.27K	348.86K	490.22K	67K	23K	0	69K
Long-Term Debt	0	0	0	0	0	0	67K	23K	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	69K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	348.86K	490.22K	0	0	0	0
Total Liabilities	1.74K	17.39K	29.44K	531.97K	1.02M	502.18K	593K	1.02M	1.29M	1.84M
Total Debt+	0	0	0	0	0	0	95K	63K	23K	104K
Net Debt	-17.03K	-3.59K	-572.77K	-337.42K	-4.42M	-2.14M	-6.53M	-6.83M	-2.79M	-2.23M
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-110.85x	-	-	-	-	-2057.40x	-	-
Total Equity+	15.29K	-13.8K	544.84K	-134.97K	5.46M	3.87M	12.04M	19.4M	11.75M	2.86M
Equity Growth %	0.04%	-1.9%	40.48%	-1.25%	41.46%	-0.29%	2.11%	0.61%	-0.39%	-0.76%
Book Value per Share	1.44	-1.30	44.92	-9.51	226.25	94.06	58.03	41.09	3.97	0.89
Total Shareholders' Equity	15.29K	-13.8K	544.84K	-134.97K	5.46M	3.87M	12.04M	19.4M	11.75M	2.86M
Common Stock	7.64K	7.64K	11.33K	14K	3.35K	4.99K	25K	3K	3K	3K
Retained Earnings	-30.51K	-60.2K	-295.09K	-2.64M	-4.81M	-9.47M	-16.9M	-31.02M	-40.31M	-50.14M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	0	0	657	-12.28K	-9.81K	63.76K	18K	-254K	-203K	-202K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Aug 2015	Aug 2016	Aug 2017	Aug 2018	Aug 2019	Aug 2020	Aug 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.5K	-18.49K	-216.82K	-1.61M	-2.79M	-4.35M	-6.14M	-8.01M	-8.21M	-8.35M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.12%	-0.37%	-10.73%	-6.43%	-0.73%	-0.56%	-0.41%	-0.3%	-0.02%	-0.02%
Net Income	-15.24K	-29.69K	-234.89K	-2.34M	-2.17M	-4.65M	-7.44M	-10.08M	-9.29M	-9.83M
Depreciation & Amortization	0	0	600	282	510	500	0	0	0	0
Stock-Based Compensation	0	0	3.33K	290K	425.11K	377.77K	1.53M	2.46M	1.02M	818K
Deferred Taxes	0	0	-600	0	-1.01M	0	0	0	0	0
Other Non-Cash Items	0	0	600	0	100K	-29.5K	7K	-211K	-641K	-279K
Working Capital Changes	1.74K	11.2K	14.14K	443.19K	-140.02K	-41.28K	-242K	-172K	703K	937K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	1.74K	11.2K	15.64K	500.7K	-180.41K	127.98K	-3K	23K	273K	480K
Cash from Investing+	0	0	0	-845	-1.5M	0	-3.44M	2.96M	3.51M	7.77M
Capital Expenditures	0	0	0	-845	-1.5M	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	15.8K	5.05K	785.35K	1.39M	8.38M	1.98M	14.11M	0	567K	112K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	5.05K	42.67K	1.84K	1.05K	3.15K	6.01M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.5K	-18.49K	-216.82K	-1.61M	-4.29M	-4.35M	-6.14M	-8.01M	-8.21M	-8.35M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.12%	-0.37%	-10.73%	-6.43%	-1.67%	-0.01%	-0.41%	-0.3%	-0.02%	-0.02%
FCF per Share	-1.27	-1.74	-17.88	-113.48	-177.86	-105.53	-29.60	-16.96	-2.77	-2.59
FCF Conversion (FCF/Net Income)	0.89x	0.62x	0.92x	0.69x	1.29x	0.93x	0.83x	0.79x	0.88x	0.85x
Interest Paid	-	-	-	-	-	-	-	-	0	0
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-101.54%	-3985.23%	-88.46%	-1143.55%	-81.57%	-99.72%	-93.45%	-64.13%	-59.63%	-134.52%
Return on Invested Capital (ROIC)	-	-	-	-	-852.31%	-253.77%	-154.15%	-85.32%	-69.16%	-158.22%
Debt / Equity	-	-	-	-	-	-	0.01x	0.00x	0.00x	0.04x
Interest Coverage	-	-	-110.85x	-	-	-	-	-2057.40x	-	-
FCF Conversion	0.89x	0.62x	0.92x	0.69x	1.29x	0.93x	0.83x	0.79x	0.88x	0.85x

Frequently Asked Questions

Growth & Financials

Artelo Biosciences, Inc. (ARTL) grew revenue by 0.0% over the past year. Growth has been modest.

Artelo Biosciences, Inc. (ARTL) reported a net loss of $10.5M for fiscal year 2024.

Dividend & Returns

Artelo Biosciences, Inc. (ARTL) has a return on equity (ROE) of -134.5%. Negative ROE indicates the company is unprofitable.

Artelo Biosciences, Inc. (ARTL) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.